Masato Kashimura
Taisho Pharmaceutical Co.
22 Papers
580 Citations
Masato Kashimura is an academic researcher from Taisho Pharmaceutical Co.. The author has contributed to research in topics: Azalide & Alkyl. The author has an hindex of 14, co-authored 22 publications.
Chat about Author
Papers
Patent
Erythromycin A derivatives
Toshifumi Asaka,Masato Kashimura,Akiko Matsuura,Tomohiro Sugimoto,Tetsuya Tanikawa,Takaaki Ishii +5 more
- 14 Oct 1997
TL;DR: Erythromycin A derivatives represented by general formula (I) or pharmaceutically acceptable salts thereof, each having a potent antibacterial activity against not only conventional erythromycin-sensitive bacteria but also resistant bacteria, wherein R?1 and R2? represent each group (a), group (b), pyridylacetyl, C?4?-C8 cycloalkylmethyl, 1,2-bis(ethoxycarbonyl)vinyl, etc.; and A represents a group represented by -OC(=O
129
Patent
6-o-methylerythromycin a derivative
Masato Kashimura,Toshifumi Asaka,Shigeo Morimoto,Katsuo Hatayama +3 more
- 22 Nov 1991
TL;DR: A 6-O-methylerythromycin (6-MTH) is a derivative represented by general formula (I) and pharmaceutically acceptable salts thereof, having a potent antibacterial activity against gram-negative bacteria and a more potent action against gram positive bacteria than that of known compounds.
81
Patent
Method for selective methylation of erythromycin a derivatives
Shigeo Morimoto,Takashi Adachi,Toshifumi Asaka,Masato Kashimura,Yoshiaki Watanabe,Kaoru Sota +5 more
- 22 Mar 1985
TL;DR: In this article, a method for the selective methylation of the hydroxy group at the 6-position of erythromycin A derivatives, which comprises reacting a compound represented by the formula R-X (wherein R is a 2-alkenyl group, a benzyl group or a substituted benzyl groups, and X is a halogen atom), reacting the resulting quaternary salt compound with a methylating agent, and then eliminating R groups of the resulting compound to give 6-O-methylerythromycin a 9-oxime, is
66
Chemical modification of erythromycins. IX. Selective methylation at the C-6 hydroxyl group of erythromycin A oxime derivatives and preparation of clarithromycin.
TL;DR: Among the 9-oxime derivatives, 2'-O,3'-N-bis(benzyloxycarbonyl)-N-demethylerythromycin A 9-[O-(2-chlorobenzyl)oxime] was the most important intermediate for the synthesis of clarithromycin (6-O-methylerathan A).
47
Synthesis and Antibacterial Activity of the Tricyclic Ketolides TE-802 and Its Analogs
TL;DR: The novel 6-O-methyl tricyclic ketolides TE-802 and its analogs exhibited good in vitro antibacterial activity against not only erythromycin-susceptible strains but also erythaiccin-resistant Staphylococcus aureus and Streptococcus pneumoniae, which are problematic pathogens of nosocomial and community-acquired respiratory tract infections, respectively.
34